Abstract:Encoded by PTPN11 , the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities. SHP2 is involved in multiple signaling cascades, including the RAS-RAF-MEK-ERK-, PI3K-AKT-, JAK-STAT- and PD-L1/PD-1- pathways. Although not mutated, activation or functional requirement of SHP2 appears to play a relevant and context-dependent dichotomous role. This mostly tumor-promoting and infrequently tumor-suppressive role exists in many cancers such as gastrointestinal tumors, pancreatic, liver and lung cancer, gynecological entities, head and neck cancers, prostate cancer, glioblastoma and melanoma. Recent studies have identified SHP2 as a potential biomarker for the prognosis of some solid tumors. Based on promising preclinical work and the advent of orally available allosteric SHP2-inhibitors early clinical trials are currently investigating SHP2-directed approaches in various solid tumors, either as a single agent or in combination regimes. We here provide a brief overview of the molecular functions of SHP2 and collate current knowledge with regard to the significance of SHP2 expression and function in different solid tumor entities, including cells in their microenvironment, immune escape and therapy resistance. In the context of the present landscape of clinical trials with allosteric SHP2-inhibitors we discuss the multitude of opportunities but also limitations of a strategy targeting this non-receptor protein tyrosine phosphatase for treatment of solid tumors.

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

STAT1 Inhibits Human Hepatocellular Carcinoma Cell Growth Through Induction of P53 and Fbxw7

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

SHP2 Associates with Nuclear Localization of STAT3: Significance in Progression and Prognosis of Colorectal Cancer

Roles of protein tyrosine phosphatase SHP2 in lung cancer

STAT3 Pathway in Cancers: Past, Present, and Future.

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Targeting STAT3 in Cancer Immunotherapy

Novel activators and small-molecule inhibitors of STAT3 in cancer

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?

Revisiting Signal Transducer and Activator of Transcription 3 (STAT3) As an Anticancer Target and Its Inhibitor Discovery: Where Are We and Where Should We Go?

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives